Single-molecule electronic multiplexed nanopore immunoassays for biomarker detection
The method of combining labeled compounds and capture compounds through nanopore platforms has solved the problem of insufficient sensitivity and multiplexed quantification of biomarker detection in the prior art, and achieved efficient, accurate detection and quantification of multiple biomarkers.
Patent Information
- Application Number
- CN201980062043.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2018-07-23
- Filing Date
- 2019-07-22
- Publication Date
- 2024-11-01
- Estimated Expiration
- 2039-07-22
AI Technical Summary
Existing biomarker detection methods have shortcomings in sensitivity and multiplexed quantification, especially when detecting multiple different biomarkers and their relative quantities, it is difficult to achieve efficient and accurate results.
Using a nanopore platform to combine labeled compounds and capture compounds, the detection and quantification of biomarkers in the sample is achieved through voltage application and current measurement methods, and the combination of multiple nanopores and different capture compounds and labeled compounds is determined. The presence and relative number of multiple biomarkers.
High sensitivity detection and multiplexed quantification of biomarkers are achieved, multiple biomarkers can be identified at the single molecule level, and their relative numbers are determined through current signal changes, improving the accuracy and efficiency of detection.
Smart Images

Figure CN113227772B_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims the benefit of U.S. Provisional Application No. 62 / 701,990, filed on July 23, 2018, the entire contents of which are hereby incorporated by reference.
[0003] Throughout this application, various publications and patents are cited. The full citations of these references can be found at the end of the specification immediately preceding the claims. The disclosures of these publications and patents are hereby incorporated into this application by reference in their entirety to more fully describe the current state of the art to which the invention belongs. Background Art
[0004] The ability to detect proteins, carbohydrates, nucleic acids, small molecules and other compounds (especially those regarded as biomarkers of cancer and other diseases) from tissue biopsy or non-invasively (e.g., from blood and urine) becomes increasingly important. These biomarkers can be tracked in individuals over time to try to diagnose diseases in early stages, to compare in different tissues, individuals or groups and to check before, during and after treatment. US2016 / 0041179 A1, Ju et al. describe a novel method for detecting compounds (analytes) using antibodies or other protein binding molecules and nanopore detectable labels. The use of nanopores is combined with ion current readings to provide a single molecule electronic detection solution, thereby providing unique opportunities for multiplexing and quantification. The latter is more sensitive than current immunological methods including ELISA (enzyme-linked immunosorbent assay), RIA (radioimmunoassay) and protein arrays and is cheaper than methods using mass spectrometry (MS) readings (samples are directly applied to MS or tandem MS or MS is performed after initial 2-D gel separation, ICAT or other procedures). In addition to using antibodies to detect and quantify antigenic compounds, the method can also be adapted to identify ligand-receptor and other protein-protein interactions and various other molecular interactions. Thus, for example, the system will have the flexibility to monitor both DNA and protein or other biomarkers simultaneously.
[0005] The focus of US2016 / 0041179 A1 is partly on connecting nanopore detectable tags to specific analytes (antigens or other molecules) using various methods. The overall method is described as follows: (1) capture antibodies, affibodies, or other antibody mimetics, aptamers, or ligands that are specific for a specific analyte (compound) are bound to each membrane-embedded nanopore in a nanopore array (or very close to each membrane-embedded nanopore in a nanopore array); (2) the labeled compound flows through the nanopore array in an electrolyte solution and binds to the specific antibody; and (3) after a voltage is applied across the membrane, a current record is obtained, thereby allowing the identification of compounds associated with the pore containing the specific nanopore. In some embodiments, the tags are connected by a cleavable linker. Different tags connected to different compounds will induce different current blockades, thereby allowing multiple compounds to be determined on the same nanopore array at the single molecule level. With a sufficient number of nanopores, quantitative or semi-quantitative results can be obtained. (See US2016 / 0041179 A1, which describes the principles of this method).
[0006] The present application includes several novel embodiments for detecting biomarkers, other biomolecules, antigens, antibodies and various molecular interactions using a single molecule electronic nanopore platform. Several examples involve the use of a labeled secondary antibody (detection antibody) that can bind to a different site on the same analyte as the initial capture antibody or to a binding partner of the original molecule attracted by the capture antibody. Summary of the invention
[0007] The present invention provides a method for detecting the presence of a compound of interest in a sample, the method comprising:
[0008] a) binding a capture compound for the compound of interest or multiple copies of the capture compound to or near the nanopore;
[0009] b) inserting the nanopore into the resistive barrier;
[0010] c) contacting the capture compound or the plurality of copies of the capture compound with the sample containing the compound of interest under conditions that allow for association of the compound of interest with the capture compound;
[0011] d) contacting the compound of interest with the tagged compound or multiple copies of the tagged compound under conditions that allow the tagged compound to attach to the compound of interest, wherein the tagged compound includes at least one tag;
[0012] e) contacting the nanopore with an electrolyte solution and applying a voltage across the resistive barrier; and
[0013] f) measuring a change in an electronic signal across the nanopore caused by entry of at least one tag of the tagged compound into the nanopore,
[0014] The presence of the compound of interest is thereby detected.
[0015] The present invention provides a method for detecting the presence of a compound of interest in a sample, the method comprising:
[0016] a) contacting the nanopore with the magnetic beads and binding compound 2 for connecting the magnetic beads to the nanopore or in the vicinity of the nanopore via binding compound 1, under conditions that allow magnetic beads with multiple copies of the capture compound to which the compound of interest is attached to be attached to or in the vicinity of the nanopore;
[0017] b) inserting the nanopore into the resistive barrier;
[0018] c) contacting the capture compound on the beads with a sample containing the compound of interest under conditions that allow binding of the compound of interest to the capture compound;
[0019] d) contacting the compound of interest with the tagged compound under conditions that allow the tagged compound to attach to the compound of interest, wherein the tagged compound includes at least one tag;
[0020] e) contacting the nanopore with an electrolyte solution and applying a voltage across the resistive barrier; and
[0021] f) measuring a change in an electronic signal across the nanopore caused by entry of at least one tag of the tagged compound into the nanopore,
[0022] The presence of the compound of interest is thereby detected.
[0023] The present invention provides a method for determining the presence and / or relative amounts of a plurality of different compounds of interest in a sample, the method comprising:
[0024] a) contacting a plurality of nanopores with a plurality of different capture compounds,
[0025] wherein each type of capture compound binds to a different type of compound of interest in the sample,
[0026] The contacting is under conditions such that each capture compound is bound to or in the vicinity of one of the plurality of nanopores;
[0027] b) inserting the plurality of nanopores into the resistive barrier;
[0028] c) contacting the plurality of different capture compounds with the sample, the sample comprising the plurality of different compounds of interest, under conditions that permit binding of each compound of interest to the capture compound;
[0029] d) contacting the plurality of different compounds of interest with a plurality of different labeled compounds,
[0030] where each type of labeled compound binds to a different type of compound of interest,
[0031] wherein each type of tagged compound comprises at least one tag,
[0032] wherein each type of tagged compound includes a different type of tag than each other type of tagged compound,
[0033] where the identity of each type of labeled compound is associated with the type of label,
[0034] The contacting is under conditions that allow each tagged compound to bind to the compound of interest;
[0035] e) contacting the plurality of nanopores with an electrolyte solution and applying a voltage across the resistive barrier;
[0036] f) measuring a change in an electronic signal across each nanopore of the plurality of nanopores caused by at least one tag of each of the tagged compounds entering the nanopore; and
[0037] g) optionally comparing the relative number of each type of tag so detected by the nanopore;
[0038] The presence and / or relative amounts of the plurality of different compounds of interest in the sample are thereby determined.
[0039] The present invention provides a method for determining the presence and / or relative amounts of a plurality of different compounds of interest in a sample, the method comprising:
[0040] a) contacting a plurality of nanopores with a plurality of different capture compounds,
[0041] wherein each type of capture compound binds to a different type of compound of interest in the sample,
[0042] wherein each type of capture compound comprises at least one tag,
[0043] wherein each type of capture compound comprises a different type of tag than each other type of capture compound,
[0044] where the identity of each type of capture compound is associated with the type of tag,
[0045] The contacting is under conditions such that each capture compound is bound to or in the vicinity of one of the plurality of nanopores;
[0046] b) inserting the plurality of nanopores into the resistive barrier;
[0047] c) contacting the plurality of nanopores with an electrolyte solution and applying a voltage across the resistive barrier;
[0048] d) measuring a change in an electronic signal across each nanopore of the plurality of nanopores caused by at least one tag of each of the capture compounds entering the nanopore, thereby determining the identity of the capture compound attached near or to each nanopore;
[0049] e) contacting the plurality of different capture compounds with the sample, the sample comprising the plurality of different compounds of interest,
[0050] wherein each compound of interest has the same type of tag attached thereto,
[0051] The contacting is under conditions that allow binding of each compound of interest to the capture compound;
[0052] f) contacting the plurality of nanopores with an electrolyte solution and applying a voltage across the resistive barrier;
[0053] g) measuring a change in an electronic signal across each nanopore of a plurality of nanopores caused by entry of the tag for each of the compounds of interest into a nanopore; and
[0054] h) optionally comparing the relative numbers of tags detected by the nanopore;
[0055] The presence and / or relative amounts of the plurality of different compounds of interest in the sample are thereby determined.
[0056] The present invention provides a method for determining molecular interactions of biomolecules, the method comprising:
[0057] a) attaching the biomolecule or multiple copies of the biomolecule to or near the nanopore;
[0058] b) inserting the nanopore into the resistive barrier;
[0059] c) contacting the biomolecule with a sample containing the putative interacting compound under conditions such that the biomolecule and the putative interacting compound interact, and optionally performing a cross-linking step to bind the biomolecule and the putative interacting compound;
[0060] d) contacting the putative interacting compound with the tagged compound under conditions that allow the tagged compound to bind to the putative interacting compound, wherein the tagged compound comprises at least one tag;
[0061] e) contacting the nanopore with an electrolyte solution and applying a voltage across the resistive barrier; and
[0062] f) measuring a change in an electronic signal across the nanopore caused by entry of at least one tag of the tagged compound into the nanopore,
[0063] Said molecular interactions of the biomolecules are thereby detected. BRIEF DESCRIPTION OF THE DRAWINGS
[0064] Figure 1 : Basic scheme for detecting proteins through nanopore sensing. (1) A capture antibody (referred to herein as the first antibody or Antibody 1) is coupled to a nanopore embedded in a membrane. The target protein (also referred to herein as the antigen or analyte) is captured by the antibody. (2) A second nano-tag detection antibody (also referred to herein as the tagged second antibody or tagged antibody 2) containing a nanopore-distinguishable tag binds to the target protein. When a voltage is applied across the membrane, the tag enters the channel of the nanopore, and the resulting blockade of ionic current specific to the tag indicates capture and therefore identification of the target protein. In variations of this basic scheme, the antibody can be replaced by an antibody mimetic, and the target can be a non-protein molecule. Although a single capture antibody is shown here, multiple copies of the capture antibody or small antibody mimetic can be attached to or near the nanopore.
[0065] Figure 2: Alpha-hemolysin nanopore (αHL) and capture antibody (Ab) are conjugated by Diels-Alder of sulfhydryl groups on two proteins. According to the method described in US9,890,426B2 for conjugating αHL to DNA polymerase, αHL protein can also be connected to antibody molecules. In this case, cysteine in two proteins is used. In the case of αHL, the protein is engineered to have a single cysteine at the desired position. In the case of antibody molecules, pretreatment with a reducing agent to cleave the disulfide bond between the cysteines exposes the SH group. Each of the two linkers has a maleimide at one end for connection with the SH group in the corresponding protein. The opposite end of the first linker has a tetrazine portion, and the opposite end of the second linker has a trans-cyclooctene (TCO) portion. Tetrazine and TCO react by a fast Diels-Alder reaction to conjugate αHL to Ab. In an optional method, the maleimide on either linker can be replaced with a succinimide ester for connection with the amino group at the N-terminus of the corresponding protein or in lysine. The maleimide group can also be replaced by an amino group for attachment to a carboxyl group (e.g., after oxidation of a carbohydrate on an antibody molecule) or by biotin for conjugation via a biotin-streptavidin interaction. In addition to conjugation between aromatic hydrazines and aromatic aldehydes, ( Biotech Co., Ltd. Biotechnologies)) The conjugation strategy is similar (protocol available from Biotech Ltd.).
[0066] Figure 3 :The structure of capture and detection antibodies with available binding sites. The difference between capture antibodies and detection antibodies lies in the antigen binding site. For a given target molecule, capture antibodies and detection antibodies will be selected to bind to different epitopes. Alternatively, the capture antibody and detection antibody can be the same, but bind to multiple epitopes on the target molecule, so that each capture antibody and detection antibody will bind to different epitope subsets on the target molecule in a random manner. In the basic scheme, the capture antibody will be conjugated to the nanopore, and the detection antibody will be connected to the target-specific nanotag. In an embodiment, only one capture antibody will bind to each nanopore, and only one tag will bind to each detection antibody. The usual connection site contains the amino group at the N-terminus of the four subunits and the primary amine on the lysine residues in the entire antibody, but this is a random process and multiple connections can be generated. After the disulfide bond (shown as a parallel line connecting the heavy chain in the hinge region) is reduced, the resulting SH bond provides less random positions for conjugation. There are also carbohydrate groups in the constant region of the heavy chain, which can also provide directional sites for conjugation.
[0067] Figure 4A : Antibodies (Abs) and nanopore detectable tags are conjugated via Diels-Alder conjugation of sulfhydryl groups on the Abs and amino groups on the tags. Figure 2 As described, in this procedure, an antibody (in this embodiment, a second antibody or a detection antibody) is connected to a maleimide-containing linker via a cysteine SH group. The nanopore detectable tag is connected to a second linker ending with a succinimide ester via a terminal amino group. The opposite ends of the first linker and the second linker have a tetrazine portion and a trans-cyclooctene (TCO) portion, respectively. Tetrazine and TCO react via a fast Diels-Alder reaction to conjugate the tag to Ab. In an optional method, the maleimide on the first linker can be replaced with a succinimide ester for connection to an amino group at the N-terminus of an antibody molecule or in a lysine. The maleimide group can also be replaced by an amino group for connection to a carboxyl group (e.g., after oxidation of a carbohydrate on an antibody molecule) or replaced by biotin for conjugation via a biotin-streptavidin interaction. In addition to conjugation between aromatic hydrazines and aromatic aldehydes, ( Biotech Ltd.) conjugation strategy is similar.
[0068] Figure 4B : Use of sulfo-SMCC 4-(N-maleimidomethyl)cyclohexane-1-carboxylic acid sulfosuccinimidyl ester for conjugating an amino-terminated tag to a cysteine group on an antibody. The sulfosuccinimidyl ester on one end of the sSMCC linker reacts with the 5' amino group on the oligonucleotide tag. The maleimide on the opposite side of the linker can then react with the -SH group on the cysteine residue in the detection (secondary) antibody, which is shown as a gray oval in this cartoon.
[0069] Figure 5: Use nanopore sensing to detect protein-protein interactions. In this embodiment, the nanopore is conjugated with an antibody to the bait protein and inserted into the membrane above the nanopore sensor. Next, a sample containing the putative interacting protein is flowed through the chip, and the bait protein and its interacting partner are captured by the bait antibody. If necessary, a cross-linking step may be included to maintain the interaction between the bait protein and the target protein. Next, antibodies to the putative target protein, each with a different distinguishable nanopore detectable label, flow through the chip in an electrolyte solution. After applying a voltage across the membrane, the label enters the channel of the nanopore, and the ion current is measured. The current blocking signature indicating a given label will reveal the binding between the bait protein and the specific target protein. With a sufficiently large array, the frequency of association of different target molecules with the bait protein can be determined. In addition to protein-protein interactions, this method can also be used to detect protein-DNA, protein-RNA, and many other molecular interactions, as long as antibodies, antibody mimics, or other recognition molecules can be used for both the bait protein and the target protein. Although a single bait protein is shown here, multiple copies of the bait protein can be connected to the nanopore.
[0070] Figure 6 : Current readings of nanopores with different unique tags. Tags were synthesized with a 30 nucleotide long oligonucleotide backbone (T) with modifications at certain positions to reduce (dSp) or enlarge (fluorescein-dT (FldT)) the cross-section of the backbone at these sites. Nanopores with a higher proportion of narrow stretches had the highest current (minimum ionic current blockade relative to open channel current), while nanopores with the widest cross-section had the lowest current (maximum ionic current blockade) (Fuller et al. 2016).
[0071] Figure 7 : Examples of tags for nanopore detection. These tags contain 30 deoxythymidine (T) nucleotides (upper left), 28 T' interrupted by two fluoresceinylated T' (FldT, upper right), 22 T' interrupted by 8 (lower left) or 3 (lower right) abasic (dSp) residues. The maximum ionic current blockade in the nanopore will be obtained with tags with FldT sites, followed by T30, then dSp3, and the lowest current blockade will be obtained with tags containing dSp8 (Fuller et al. 2016).
[0072] Figure 8: Examples of tags for nanopore sensing. Tags can have various backbones, e.g., oligonucleotides, PEG, spermine, alkanes, abasic sites (examples shown in the first two rows), alternative bases and similarly sized substituents (examples shown in the third and fourth rows), and different dyes or other bulky substituents attached to the bases (fluorescein-dT in the fourth row; other example fluorescent dyes shown in the last row).
[0073] Fig. 9 : Use of magnetic beads decorated with capture antibodies to fish out biomarkers of interest. In this embodiment, magnetic beads inlaid with antibodies are mixed with the sample to capture the target biomarker. The beads are collected and conjugated to nanopores inserted into the lipid membrane directly or through a chemical linker (interaction between binding compound 1 such as biotin and binding compound 2 such as streptavidin). Subsequent binding of labeled detection antibodies allows determination of the biomarker at a given position on the array. This method is designed to increase sensitivity.
[0074] Fig. 10A : Nanopore detection of labeled serum antibodies using capture antigen. In this example, proteins such as antibodies in serum are conjugated to nanopore detectable tags using standard labeling procedures. The labeled antibodies are captured from the serum sample using antigens attached to the nanopore. A voltage gradient is applied across the membrane to capture the tags, and the current is recorded. Identification of its specific tag signal will reveal the presence of the antibody of interest in the serum sample. Although shown here as a single antigen, multiple copies of the antigen can be attached to the nanopore.
[0075] Fig. 10B : Nanopore detection of serum antibodies using streptavidin capture. In this example, serum antibodies were conjugated to nanopore detectable labels using standard procedures, and the antigens of these serum antibodies were biotinylated. Biotinylated antigens were captured using streptavidin molecules attached to the nanopore via biotin-streptavidin interactions. Next, the labeled serum antibodies were bound to the complex on the nanopore. A voltage gradient was applied across the membrane to capture the label in the nanopore channel, and the current was recorded. Identification of its specific label signal will reveal the presence of the antibody of interest. The placement of biotin and streptavidin can be reversed.
[0076] Fig. 10C: Nanopore detection of serum antibodies using anti-digoxigenin antibody capture. In this example, serum antibodies are conjugated to nanopore detectable labels using standard procedures, and the antigens of these serum antibodies are derivatized with digoxigenin. Anti-digoxigenin antibody molecules attached to the nanopore are used to capture digoxigenin-labeled antigens through digoxigenin-anti-digoxigenin interactions. Next, the labeled serum antibodies are bound to the complex on the nanopore. A voltage gradient is applied across the membrane to capture the label in the nanopore channel, and the current is recorded. The identification of its specific label signal will reveal the presence of the antibody of interest. The placement of biotin and streptavidin can be reversed.
[0077] Fig.11A : Nanopore detection of serum antibodies using capture antigen and labeled secondary antibody. In this example, the antigen is bound to the nanopore and used to capture specific serum antibodies. Next, the labeled secondary antibody (antibody raised against the Fc portion of the captured antibody) is passed through the nanopore chip. A voltage gradient is applied across the membrane to capture the tag, and the current is recorded. The identification of its specific tag signal will reveal the presence of the antibody of interest in the serum sample. Although shown here as a single antigen, multiple copies of the antigen can be connected to the nanopore.
[0078] Fig. 11B : Nanopore detection of serum antibodies using the biotin-streptavidin interaction between serum antibodies and labels. In this example, serum antibodies are biotinylated and streptavidin is linked to a nanopore detectable label. An antigen that can be recognized by serum antibodies is linked to the nanopore using standard procedures. This antigen will capture the biotinylated serum antibodies. Next, the label is linked to the complex on the nanopore using incubation with labeled streptavidin. A voltage gradient is applied across the membrane to capture the label in the nanopore channel, and the current is recorded. The identification of its specific label signal will reveal the presence of the antibody of interest. The placement of biotin and streptavidin can be reversed.
[0079] Fig. 11C : Nanopore detection of serum antibodies using digoxin-anti-digoxin antibody interactions between serum antibodies and labels. In this example, serum antibodies are derivatized with digoxin, and anti-digoxin antibodies are linked to nanopore detectable labels. An antigen that can be recognized by serum antibodies is linked to the nanopore using standard procedures. This antigen will capture the digoxin-derivatized serum antibodies. Next, the label is linked to the complex on the nanopore using incubation with labeled anti-digoxin antibodies. A voltage gradient is applied across the membrane to capture the label in the nanopore channel, and the current is recorded. Identification of its specific label signal will reveal the presence of the antibody of interest. The placement of biotin and streptavidin can be reversed.
[0080] Fig.12: Nanopore detection of serum antibodies using virus particles connected to nanopores and tagged primary antibodies against viral coat proteins. In this method, proteins in serum containing any viral antibodies are conjugated to nanopore detectable tags. The nanopore is conjugated to the virus particles or virus particle fragments through a chemical linker, such as through a biotin-streptavidin interaction. Tagged serum antibodies raised against viral coat proteins due to current or previous viral infection are attracted to the virus particles on the nanopore. The revelation of these antibodies is due to the presence of the nanopore tag, which produces an ionic current blockade when the tag is captured in the nanopore channel after a voltage is applied across the membrane.
[0081] Fig.13 : Nanopore detection of serum antibodies using nanopore-linked viral particles and labeled secondary antibodies. Fig.12 In this alternative to the scheme shown, proteins in serum are not tagged; instead, a nanopore detectable tag is conjugated to a secondary antibody raised against the Fc portion of the serum antibody. The nanopore is conjugated to a viral particle or viral particle fragment connected to the nanopore through a chemical linker, such as through the interaction between biotin and streptavidin. Serum antibodies raised against viral coat proteins due to current or previous viral infection are attracted to the viral particles on the nanopore. The revelation of these antibodies is due to the presence of the nanopore tag on the secondary antibody, which produces an ionic current blockade when the tag is captured in the nanopore channel after a voltage is applied across the membrane.
[0082] Fig.14 : Use of magnetic beads decorated with viral antigens for fishing out antiviral antibodies present in serum or other samples due to viral infection. In this embodiment, magnetic beads inlaid with viral proteins are used to capture antibodies in serum. After the complex is chemically linked to the nanopore through the interaction between binding compound 1 such as biotin and binding compound 2 such as streptavidin, a labeled secondary antibody (e.g., goat-anti-rabbit antibody) directed against the Fc portion of the captured antibody is used to determine the presence of antiviral antibodies. The method has the potential to improve sensitivity.
[0083] Fig.15: Nanopore detection of antigen-antibody complexes in serum using capture antibodies and labeled detection antibodies. In this embodiment, the capture antibody is combined with a nanopore and used to capture specific serum antigen-antibody complexes. Next, a labeled secondary antibody (an antibody proposed for the Fc portion of the captured antibody in the complex) is passed through the nanopore chip. A voltage gradient is applied across the membrane to capture the label, and the current is recorded. The identification of the label signal will reveal the presence of the antigen-antibody complex of interest in the serum sample. This method can be further modified by using magnetic beads containing capture antibody clusters to further improve sensitivity. Although a single capture antibody is shown here, multiple copies of the capture antibody or small antibody mimics can be connected to the nanopore.
[0084] Fig.16 : Multiplexing and quantification of target proteins using nanopore arrays. Figure 1 An example of the scheme shown, in which capture antibodies for different targets are distributed in random positions across the nanopore array in equal proportions; these positions are unknown at the beginning of the experiment (A). After flowing into the sample with a mixture of its target and other molecules (B), an equimolar mixture of nano-tag detection antibodies for different targets is flowed onto the array (C). These labeled antibodies will bind to the target, which has been bound to the capture antibody according to its ratio in the sample. The voltage applied across the membrane will allow the label to be captured by a single nanopore associated with each position on the array, and the resulting blocking current displayed by the different depths of the drop in the trace adjacent to each nanopore will determine which target protein is captured at each position (D), and the different depths indicate different labels. With a large enough array, the ratio of the target protein in the sample can be determined by counting the number of positions showing each blocking current. It should be noted that when the target is not bound to the capture antibody, an open channel current is obtained because there is no associated label.
[0085] Fig.17 : Cleavable linkers for attaching nanopore tags to antibodies or other molecules. Shown here are five examples of cleavable groups that can be installed in linkers that attach tags to detection antibodies or other detection molecules, and the chemicals that can be used to cleave the linkers at these locations while leaving the protein intact.
[0086] Fig.18:In this embodiment, the capture antibody for the specific target molecule is connected to the specific nanopore tag through a cleavable linker. A voltage gradient is applied across the membrane to capture the tag, and the current is recorded. The identification of the tag signal will reveal which capture antibody is present at the position of the array. The tag is cleaved, and this antibody is used to capture the specific target molecule from serum or other sources. The classification of different target molecules in the serum is pre-marked with a general nanopore tag that is different from the specific tag on the capture antibody. A voltage gradient is applied across the membrane again to capture a new tag, and the current is recorded. The initial current record indicates which antibody is present and therefore which target molecule can bind, and the second current indicates the actual binding of the target molecule. Counting this combination event across the chip will reveal the relative number of different target molecules in the serum. (If the tag on the antibody is not cleaved, applying a pulse voltage across the membrane will cause the second record to be a series of both specific tags and general tag readings.)
[0087] Fig.19 : Synthesis of cleavable trifunctional linker NHS ester-azo TCO / PEG3-maleimide. TCO is first coupled to Fmoc-protected lysine, which can be further coupled to the azo linker via carboxylic acid activation and amide bond formation. Removal of the Fmoc group allows one more coupling step using maleimide NHS ester. Subsequent activation of the azo linker acid provides NHS ester-azo TCO / PEG3-maleimide.
[0088] Fig. 20 : Preparation of nanopore-capture antibody-cleavable tag conjugates. Fig.19 The cleavable trifunctional linker NHS ester-azo TCO / PEG3-maleimide synthesized in the present invention is reacted with an amino tag to produce a tag-azo TCO / PEG3-maleimide conjugate, which can be easily reacted with a tetrazine-modified capture antibody via TCO-tetrazine addition. The resulting tag-azo capture antibody-maleimide conjugate is further reacted with α-hemolysin-SH via thiol-ene addition to provide a nanopore cleavable tag-capture antibody conjugate, wherein the tag can be removed by azo reduction and cleavage upon sodium dithionite treatment. DETAILED DESCRIPTION
[0089] The present invention provides a method for detecting the presence of a compound of interest in a sample, the method comprising:
[0090] a) binding a capture compound for the compound of interest or multiple copies of the capture compound to or near the nanopore;
[0091] b) inserting the nanopore into the resistive barrier;
[0092] c) contacting the capture compound or the plurality of copies of the capture compound with the sample containing the compound of interest under conditions that allow for association of the compound of interest with the capture compound;
[0093] d) contacting the compound of interest with the tagged compound or multiple copies of the tagged compound under conditions that allow the tagged compound to attach to the compound of interest, wherein the tagged compound includes at least one tag;
[0094] e) contacting the nanopore with an electrolyte solution and applying a voltage across the resistive barrier; and
[0095] f) measuring a change in an electronic signal across the nanopore caused by entry of at least one tag of the tagged compound into the nanopore,
[0096] The presence of the compound of interest is thereby detected.
[0097] In an embodiment of the present invention, step c) occurs before step a). In an embodiment of the present invention, step d) occurs before step c). In an embodiment of the present invention, step b) occurs before step a).
[0098] The present invention provides a method for detecting the presence of a compound of interest in a sample, the method comprising:
[0099] a) contacting the nanopore with the magnetic beads and binding compound 2 for connecting the magnetic beads to the nanopore or in the vicinity of the nanopore via binding compound 1, under conditions that allow magnetic beads with multiple copies of the capture compound to which the compound of interest is attached to be attached to or in the vicinity of the nanopore;
[0100] b) inserting the nanopore into the resistive barrier;
[0101] c) contacting the capture compound on the beads with a sample containing the compound of interest under conditions that allow binding of the compound of interest to the capture compound;
[0102] d) contacting the compound of interest with the tagged compound under conditions that allow the tagged compound to attach to the compound of interest, wherein the tagged compound includes at least one tag;
[0103] e) contacting the nanopore with an electrolyte solution and applying a voltage across the resistive barrier; and
[0104] f) measuring a change in an electronic signal across the nanopore caused by entry of at least one tag of the tagged compound into the nanopore,
[0105] The presence of the compound of interest is thereby detected.
[0106] In an embodiment of the present invention, step c) occurs before step a). In an embodiment of the present invention, step d) occurs before step c). In an embodiment of the present invention, step b) occurs before step a).
[0107] The present invention provides a method for determining the presence and / or relative amounts of a plurality of different compounds of interest in a sample, the method comprising:
[0108] a) contacting a plurality of nanopores with a plurality of different capture compounds,
[0109] wherein each type of capture compound binds to a different type of compound of interest in the sample,
[0110] The contacting is under conditions such that each capture compound is bound to or in the vicinity of one of the plurality of nanopores;
[0111] b) inserting the plurality of nanopores into the resistive barrier;
[0112] c) contacting the plurality of different capture compounds with the sample, the sample comprising the plurality of different compounds of interest, under conditions that permit binding of each compound of interest to the capture compound;
[0113] d) contacting the plurality of different compounds of interest with a plurality of different labeled compounds,
[0114] where each type of labeled compound binds to a different type of compound of interest,
[0115] wherein each type of tagged compound comprises at least one tag,
[0116] wherein each type of tagged compound includes a different type of tag than each other type of tagged compound,
[0117] where the identity of each type of labeled compound is associated with the type of label,
[0118] The contacting is under conditions that allow each tagged compound to bind to the compound of interest;
[0119] e) contacting the plurality of nanopores with an electrolyte solution and applying a voltage across the resistive barrier;
[0120] f) measuring a change in an electronic signal across each nanopore of the plurality of nanopores caused by at least one tag of each of the tagged compounds entering the nanopore; and
[0121] g) optionally comparing the relative number of each type of tag so detected by the nanopore;
[0122] The presence and / or relative amounts of the plurality of different compounds of interest in the sample are thereby determined.
[0123] The present invention provides a method for determining the presence and / or relative amounts of a plurality of different compounds of interest in a sample, the method comprising:
[0124] a) contacting a plurality of nanopores with a plurality of different capture compounds,
[0125] wherein each type of capture compound binds to a different type of compound of interest in the sample,
[0126] wherein each type of capture compound comprises at least one tag,
[0127] wherein each type of capture compound comprises a different type of tag than each other type of capture compound,
[0128] where the identity of each type of capture compound is associated with the type of tag,
[0129] The contacting is under conditions such that each capture compound is bound to or in the vicinity of one of the plurality of nanopores;
[0130] b) inserting multiple nanopores into the resistive barrier;
[0131] c) contacting the plurality of nanopores with an electrolyte solution and applying a voltage across the resistive barrier;
[0132] d) measuring a change in an electronic signal across each nanopore of the plurality of nanopores caused by at least one tag of each of the capture compounds entering the nanopore, thereby determining the identity of the capture compound attached near or to each nanopore;
[0133] e) contacting the plurality of different capture compounds with the sample, the sample comprising the plurality of different compounds of interest,
[0134] wherein each compound of interest has the same type of tag attached thereto,
[0135] The contacting is under conditions that allow binding of each compound of interest to the capture compound;
[0136] f) contacting the plurality of nanopores with an electrolyte solution and applying a voltage across the resistive barrier;
[0137] g) measuring a change in an electronic signal across each nanopore of a plurality of nanopores caused by entry of the tag for each of the compounds of interest into a nanopore; and
[0138] h) optionally comparing the relative numbers of tags detected by the nanopore;
[0139] The presence and / or relative amounts of the plurality of different compounds of interest in the sample are thereby determined.
[0140] In an embodiment of the present invention, step b) occurs before step a).
[0141] In an embodiment of the present invention, the tag attached to the capture compound is cleaved after step d).
[0142] In an embodiment of the present invention, the capture compound or the multiple copies of the capture compound are connected to the nanopore. In an embodiment of the present invention, the capture compound or the multiple copies of the capture compound are connected near the nanopore. In an embodiment of the present invention, the capture compound is an antibody. In an embodiment of the present invention, the capture compound is an antibody mimetic. In an embodiment of the present invention, the antibody mimetic is one of an affibody, an avibody, an affimer, a nanoclamp, a medicament or an organic small molecule.
[0143] In an embodiment of the present invention, the labeled compound is an antibody. In an embodiment of the present invention, the labeled compound is an antibody mimetic. In an embodiment of the present invention, the antibody mimetic is one of an affibody, an affimer, an affimer, a nanotweezer, a drug or an organic small molecule.
[0144] In an embodiment of the present invention, the one or more compounds of interest are antigens. In an embodiment of the present invention, the antigen is one of a biomarker, a protein, a lipid, a carbohydrate, a DNA, a glycoprotein, a lipoprotein, a viral particle or other complex molecules.
[0145] The present invention provides a method for determining molecular interactions of biomolecules, the method comprising:
[0146] a) attaching the biomolecule or multiple copies of the biomolecule to or near the nanopore;
[0147] b) inserting the nanopore into the resistive barrier;
[0148] c) contacting the biomolecule with a sample containing the putative interacting compound under conditions such that the biomolecule and the putative interacting compound interact, and optionally performing a cross-linking step to bind the biomolecule and the putative interacting compound;
[0149] d) contacting the putative interacting compound with the tagged compound under conditions that allow the tagged compound to bind to the putative interacting compound, wherein the tagged compound comprises at least one tag;
[0150] e) contacting the nanopore with an electrolyte solution and applying a voltage across the resistive barrier; and
[0151] f) measuring a change in an electronic signal across the nanopore caused by entry of at least one tag of the tagged compound into the nanopore,
[0152] Said molecular interactions of the biomolecules are thereby detected.
[0153] In an embodiment of the present invention, step b) occurs before step a).
[0154] In an embodiment of the present invention, the biomolecule is connected to the nanopore via a flexible linker.
[0155] In an embodiment of the present invention, the tag is connected to the tagged compound via a cleavable linker, and the tag is cleaved from the tagged compound after step d).
[0156] In an embodiment of the present invention, the biomolecule is one of a biomarker, a protein, a lipid, a carbohydrate, a DNA, a glycoprotein, a lipoprotein, a viral particle or other complex molecules.
[0157] In an embodiment of the present invention, the putative interacting molecule is one of a biomarker, a protein, a lipid, a carbohydrate, a DNA, a glycoprotein, a lipoprotein, a viral particle or other complex molecules.
[0158] In an embodiment of the present invention, the labeled compound is one of a biomarker, a protein, a lipid, a carbohydrate, a DNA, a glycoprotein, a lipoprotein, a viral particle or other complex molecules.
[0159] In embodiments of the methods described herein, the one or more tags comprise a polymer molecule. In embodiments of the invention, the polymer molecule is a polymer comprising one or more of PEG, an alkane, a peptide, a polypeptide, a polynucleotide, or any combination thereof. In embodiments of the invention, the tag further comprises a modification that enlarges or reduces the diameter of the tag within the nanopore. In embodiments of the invention, the tag further comprises a modification that changes the charge of the tag. In embodiments of the invention, the tag comprises one or more of: dSP, C3, C n , PEG, pyrrolidine, spermine, spermidine, nitropyrrole, nitroindole, muscimol, benzimidazole, benzene, 7-deazapurine, 5-substituted pyrimidine, fluorescein-dT, fluorescein, rhodamine, ROX, cyanine dyes, or any combination thereof.
[0160] In an embodiment of the method described herein, the nanopore is a solid-state nanopore, wherein step b) occurs before step a), or wherein step b) is omitted. In an embodiment of the method described herein, the nanopore is a solid-state nanopore, in which case the capture compound is attached to or near the nanopore in a first step. In an embodiment of the invention, the resistive barrier comprises graphene, molybdenum disulfide or silicon nitride.
[0161] In embodiments of the methods described herein, the nanopore comprises a biological nanopore. In embodiments of the invention, the nanopore is α-hemolysin. In embodiments of the invention, the nanopore is α-hemolysin, MspA or OmpG or FraC or Aeromonas lysin or other transmembrane pore complexes of the β-barrel type or other types of transmembrane pore complexes. In embodiments of the invention, the resistive barrier is a lipid bilayer.
[0162] In an embodiment of the present invention, the nanopore is a hybrid protein-solid-state nanopore.
[0163] In an embodiment of the invention, said nanopore comprises an integrated electronic sensor.
[0164] As used herein and unless otherwise stated, each of the following terms shall have the definition set forth below.
[0165] "Antibodies" shall include, but are not limited to: (a) immunoglobulin molecules comprising two heavy chains and two light chains and recognizing antigens; (b) polyclonal or monoclonal immunoglobulin molecules; and (c) monovalent or divalent fragments thereof. Immunoglobulin molecules may be derived from any commonly known class, including, but not limited to, IgA, secretory IgA, IgG, IgE, and IgM. IgG subclasses are well known to those skilled in the art and include, but are not limited to, human IgG1, IgG2, IgG3, and IgG4. Antibodies may be both naturally occurring and non-naturally occurring. In addition, antibodies include chimeric antibodies, fully synthetic antibodies, single-chain antibodies, and fragments thereof. Antibodies may be human or non-human. Antibody fragments include, but are not limited to, Fab fragments, Fv fragments, and other antigen binding fragments.
[0166] "Nanopore" includes, for example, a structure including: (a) a first compartment and a second compartment separated by a physical barrier, the barrier having at least one hole having a diameter of, for example, about 1 to 10 nm; and (b) a member for applying an electric field across the barrier so that charged molecules such as DNA, nucleotides, nucleotide analogs, or tags can pass from the first compartment through the hole into the second compartment. The nanopore ideally further includes a member for measuring the electronic signature of the molecule passing through its barrier. The nanopore barrier may be synthetic or partially naturally occurring. The barrier may include, for example, a lipid bilayer having α-hemolysin, oligomeric protein channels such as porins, and synthetic peptides therein. The barrier may also include an inorganic plate having one or more holes of suitable size. In this article, "nanopore", "nanopore barrier", and "hole" in the nanopore barrier are sometimes used equivalently. It should be understood that the electric field of the nanopore may be adjustable. It should also be understood that charged molecules such as DNA, nucleotides, nucleotide analogs, or tags do not need to pass through the hole from the first compartment to reach the second compartment to generate an electronic signature. Such electronic signatures can be generated by the positioning of molecules within the hole.
[0167] Nanopore devices are known in the art, and nanopores and methods employing nanopores are disclosed in: U.S. Pat. Nos. 7,005,264; 7,846,738; 6,617,113; 6,746,594; 6,673,615; 6,627,067; 6,464,842; 6,362,002; 6,267,872; 6,015,714; 5,795,782; and U.S. Publication Nos. 2004 / 0121525, 2003 / 0104428, and 2003 / 0104428, each of which is hereby incorporated by reference in its entirety.
[0168] The "blocking signature" of a molecule passing through a hole by applying an electric field (e.g., an applied voltage) should include, for example, the duration of the molecular tag passing through the hole and the current amplitude observed during the passage. It is envisioned that the blocking signature of the molecule, and the blocking signature can be, for example, a plot of the current (e.g., pA) for the molecule to pass through the hole by applying an electric field to the time. Alternatively, for molecules that do not pass through the hole, a blocking signature can also be determined. It is also envisioned that the blocking signature of such molecules, and the blocking signature can be, for example, a plot of the current (e.g., pA) for the molecule to enter the hole or pass adjacent to the hole to the time. In this article, "blocking signature", "blocking signal" and "electronic signature" are sometimes used equivalently. In this article, "voltage" and "electric field" are sometimes used equivalently.
[0169] A specific event map was constructed as a plot of translocation time versus blockade current. This specific event map (also called blockade signature) was used to distinguish molecules by single channel recording techniques based on characteristic parameters like translocation current, translocation duration and their corresponding scatter in the map.
[0170] As used herein, a "tag" or "tag moiety" is any chemical group or molecule capable of producing a unique blocking signature detectable with a nanopore. In some cases, the tag comprises one or more of: glycol, an amino acid, a carbohydrate, a peptide, a dye, a fluorescent compound, a chemiluminescent compound, a mononucleotide, a dinucleotide, a trinucleotide, a tetranucleotide, a pentanucleotide, a hexanucleotide, a polynucleotide, a nucleotide monophosphate, a nucleotide diphosphate, a nucleotide polyphosphate, a fatty acid, an aromatic acid, an unsubstituted alcohol or thiol, an alcohol or thiol substituted with one or more halogens, a cyano group, a nitro group, an alkyl group, an alkenyl group, an alkynyl group, an azido group, or a combination thereof.
[0171] As used herein, unless otherwise specified, a tag moiety that is different or distinguishable from a tag moiety of a reference molecule means that the tag moiety has a chemical structure that is different from the chemical structure of the other / referenced tag moiety. A tag moiety that is different or distinguishable from a tag moiety of a reference molecule can also mean that the tag moiety has a blocking signature that is different from the blocking signature of the other / referenced tag moiety.
[0172] As used herein, a tag "positioned" within a well is a tag that is located within or adjacent to a well. A tag positioned within a well does not necessarily pass through the well or displace the well.
[0173] As used herein, a "proteinaceous" compound means any biological polymer formed from amino acids, such as a peptide, protein, antibody, antigen, or a fragment or portion thereof. Such compounds may be naturally occurring or non-naturally occurring.
[0174] As used herein, "alkyl" includes both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms and may be unsubstituted or substituted. Thus, C1-Cn as in "C1-Cn alkyl" includes groups having 1, 2, ..., n-1, or n carbons in a straight or branched arrangement. For example, "C1-C5 alkyl" includes groups having 1, 2, 3, 4, or 5 carbons in a straight or branched arrangement and specifically includes methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, and pentyl.
[0175] As used herein, the term "alkenyl" refers to a straight or branched non-aromatic hydrocarbon group containing at least one carbon-carbon double bond, and up to the maximum possible number of non-aromatic carbon-carbon double bonds may be present and may be unsubstituted or substituted. For example, "C2-C5 alkenyl" means an alkenyl group having 2, 3, 4 or 5 carbon atoms and up to 1, 2, 3 or 4 carbon-carbon double bonds, respectively. Alkenyl includes ethenyl, propenyl and butenyl.
[0176] The term "alkynyl" refers to a straight or branched chain hydrocarbon group containing at least one carbon-carbon triple bond, and up to the maximum possible number of non-aromatic carbon-carbon triple bonds may be present and may be unsubstituted or substituted. Thus, "C2-C5 alkynyl" means an alkynyl group having 2 or 3 carbon atoms and 1 carbon-carbon triple bond or having 4 or 5 carbon atoms and up to 2 carbon-carbon triple bonds. Alkynyl includes ethynyl, propynyl and butynyl.
[0177] The term "substituted" refers to a functional group such as an alkyl or hydrocarbyl group as described above, wherein at least one bond contained to a hydrogen atom is replaced by a bond to a non-hydrogen or non-carbon atom, provided that normal valence is maintained and one or more substitutions produce a stable compound. Substituted groups also include groups in which one or more bonds to one or more carbons or one or more hydrogens are replaced by one or more bonds to a heteroatom (including double or triple bonds). Non-limiting examples of substituents include the above functional groups and, for example, N, for example, to form -CN.
[0178] It should be understood that the substituents and substitution patterns on the compounds of the present invention can be selected by one of ordinary skill in the art to provide compounds that are chemically stable and can be readily synthesized from readily available starting materials by techniques known in the art and those listed below. If a substituent is itself substituted with more than one group, it should be understood that these multiple groups can be on the same carbon or on different carbons, as long as the result is a stable structure.
[0179] In selecting compounds of the present invention, one of ordinary skill in the art will recognize that the various substituents, ie, R1, R2, etc., should be selected according to well-known principles of chemical structural connectivity.
[0180] In the compound structures depicted herein, hydrogen atoms other than those on ribose and deoxyribose are generally not shown. However, it should be understood that there are sufficient hydrogen atoms on the represented carbon atoms to satisfy the octet rule.
[0181] Where a range of values is provided, it is to be understood that each intermediate integer of the value between the upper and lower limits of the range (and one tenth of each intermediate integer of the value unless the context clearly specifies otherwise) and any other stated value or intermediate value in the stated range are encompassed within the present invention unless the context clearly specifies otherwise. The upper and lower limits of these smaller ranges may be independently included in smaller ranges and are also encompassed within the present invention, subject to any explicitly excluded limits in the stated ranges. Where the stated range includes one or both of the limits, the range excluding (i) either or (ii) both of those included limits is also encompassed within the present invention.
[0182] The terms first antibody and second antibody (first st ) antibody and the second (2 nd ) antibodies; antibody 1 and antibody 2; capture antibody and detection antibody) are not equivalent to primary and secondary antibodies, which are generally not suitable for use in the methods disclosed herein, except for Example 8. The secondary antibody is an antibody raised against the primary antibody, which in turn is raised against the antigen of interest. In the subject application, both the first antibody and the second antibody are raised against the same antigen protein or other molecule or against two interacting molecules.
[0183] Target, target molecule, antigen, antigenic molecule and biomarker are used interchangeably in this document. Examples 8 and 12 are exceptions, where the target is an antibody or antigen-antibody complex, rather than just an antigen. It should be understood that some antigens of interest may not be established as biomarkers, and some biomarkers may not be antigenic, but may have binding partners that can be used in this method. Analyte is another term sometimes used to refer to a target molecule.
[0184] In this context, the term complex molecule is taken to include any molecular compound such as lipoproteins or glycoproteins or complexes including but not limited to protein complexes and intact virions.
[0185] Some embodiments of the invention disclosed herein include the possibility of tagging a secondary antibody (detection antibody) that binds to a different epitope on the same analyte as the primary antibody.
[0186] All combinations of the various elements described herein are within the scope of the present invention. All sub-combinations of the various elements described herein are also within the scope of the present invention.
[0187] The present invention will be better understood by reference to the experimental details that follow, but those skilled in the art will readily appreciate that the specific experiments described in detail are merely illustrative of the invention as more fully described in the claims below.
[0188] Experimental details and discussion
[0189] As a general case, Figure 1 As outlined in and described more fully in Example 7, the procedure would be as follows: (1) a capture antibody, affibody, or other antibody mimetic, aptamer, or ligand specific for a particular analyte (compound) would bind to (or be in close proximity to) individual membrane-embedded nanopores in the nanopore array; (2) a sample containing the analyte to be identified would flow through the nanopore array and bind to the specific capture antibody or antibody mimetic; (3) in a version of the antibody sandwich technique, a labeled secondary antibody (or affibody, or other antibody mimetic, aptamer, or ligand specific for a particular analyte (compound)) would flow in an electrolyte solution through the nanopore array and bind to different sites on the analyte; and (4) upon application of a voltage across the membrane, a current recording would be obtained, allowing identification of compounds associated with pores containing the particular nanopore. The concept can be further extended to a form where the reaction steps (1-3) related to binding of biomarkers are performed in solution phase and the enriched nanopore-antibody-biomarker tag antibody complexes are then applied to a nanopore array and evaluated at the single molecule level.
[0190] Different tags attached to secondary antibodies against different analytes will induce different current blockades, allowing multiple targets to be determined on the same nanopore array. With a sufficient number of nanopores, quantitative or semi-quantitative results can be obtained ( Figure 1 ).
[0191] US2016 / 0041179 A1, Ju et al. describe the covalent attachment of specific tags to specific analytes (compounds of interest). This tagging is performed before the analyte flows through the chip. In the novel method disclosed herein, a labeled second antibody (detection antibody) is used in conjunction with a capture antibody for the same target, thereby generating a flexible method for single molecule detection through a nanopore, thereby allowing a variety of multiplexing and quantitative strategies. As long as multiple (or even the same) antibodies can be used for protein biomarkers that bind to it at different epitopes, no special sample preparation is required. Unlike protein arrays where the binding of antibodies to surfaces may reduce the ability of antibodies to bind to antigens, the first antibody is connected to the nanopore via a flexible linker and should retain the ability of the first antibody to bind to its antigen. In addition, the resulting complex should be easily accessible to the labeled second antibody. The invention disclosed herein retains all the advantages of nanopore-based methods, including: (1) single molecule electronic readout, resulting in rapid speed and high accuracy; (2) high throughput, due to the parallelization of readouts over many nanopores; (3) multiplexing, based on the ability to easily distinguish multiple tags and utilize multiple flow cells; (4) the ability to quantify protein biomarker levels, due to the digital nature of the output (essentially counting electronic readouts over a large number of nanopores); and (5) small instrument size and cost. The method can provide substantially higher sensitivity and dynamic range than fluorescent tag-based immunodetection methods.
[0192] Variations on the above general approach can involve attaching multiple capture antibodies or small antibody mimics (e.g., Affibodies, Avibodies(TM), affimers, nanotweezers) to or near the nanopore, typically through a flexible linker, and using multiple copies of the tag on the detection antibody.
[0193] Example 1: Linking the capture antibody to the nanopore. Linking the capture antibody (first antibody or Antibody 1) to the nanopore is the same in both the original and new methods. A person skilled in the art will be aware of several methods for derivatizing antibodies with key amino acid residues such as lysine or cysteine. These linkages can involve homobifunctional or heterobifunctional reagents or dual linker systems, such as those available from Biotech Ltd. acquired the system ( Reagents) or systems involving Diels-Alder reactions (see below). Other possibilities include the generation of fusion proteins incorporating SpyCatcher / SpyTag interaction partners (Zakeri et al. 2012). In one embodiment, the Fc portion of an immunoglobulin (Ig) is bound to a nanopore, leaving the Fab'2 portion free to react with the antigen. The presence of an NHS ester or isothiocyanate group on the end of the linker molecule will allow it to be linked to the N-terminal amino group of the antibody or the primary amino group on the lysine. Although lysine is present in both the Fc and Fab portions, this simple approach will generate a larger proportion of acceptable connections. A second possibility is to connect to a cysteine residue in the hinge region of the Ig molecule. The presence of maleimide or iodoacetamide on the linker will allow it to be linked to the SH group on the cysteine, which will require the reduction of the disulfide bond connecting the two cysteines. This will affect the binding of the two large subunits of the Ig to each other. Although this may slightly reduce the overall affinity of the binding, it is one of the simplest and more site-directed alternatives. Another attractive possibility is to conjugate amine or hydrazide-modified linkers to periodate-oxidized carbohydrate groups present on the Fc constant domains, followed by reduction of the resulting Schiff base with borohydride. Other conjugation possibilities include click chemistry (e.g., alkyne-azide) reactions and biotin-streptavidin interactions. A Diels-Alder heterobifunctional conjugation strategy for linking DNA polymerase to α-hemolysin (αHL) nanopores has been reported previously (US2016 / 0041179 A1), and the connection of antibodies to these nanopores would follow the same approach ( Figure 2 ). The implementation of the above conjugation strategy utilizes the α-hemolysin mutant proteins that have been generated in which a single cysteine has been introduced at a specific position on one or more of the seven pore subunits, thereby making it specifically reactive toward maleimide and other thiol-reactive moieties. Finally, a directed attachment strategy based on the incorporation of orthogonal amino acid analogs into proteins can be implemented. Regardless of the specific method used, the goal is to attach a single or only a few copies of a specific antibody to each nanopore in the nanopore array. (For the structure and conjugation sites of the capture antibodies, see Figure 3 ) An alternative strategy is disclosed herein in which beads containing clusters of the same capture antibody are used to increase the likelihood of target capture (e.g., Fig. 9 ).
[0194] Various protein nanopores and solid-state nanopores can be used. Although α-hemolysin nanopores containing various mutant forms have been used in sequencing by synthesis studies (US2018 / 0073071 A1, US9,890,426 B2, US2015 / 0368710 A1, US2015 / 0111759 A1, US8,889,348 B2, US2013 / 0264207 A1, Kumar (2012), Fuller (2016), and Stranges (2016)), other protein nanopores such as MspA (Derrington et al. 2010), OmpG (Sanganna et al. 2013), and α-hemolysin nanopores can be used. Gari et al. 2019), FraC (Huang et al. 2019), Aeromonas lysin (Wang et al. 2018), anthrax protective antigen (Jiang et al. 2015), other β-barrel transmembrane pores (Heuck et al. 2001), and various commercial custom-made nanopores, their mutants and derivatives.
[0195] For these, most of the above-mentioned connection and conjugation chemistries can be utilized. Other options include solid-state nanopores based on graphene (Merchant and Drndic 2012), MoS2 (Graf et al. 2019), Si3N4 (Rollings et al. 2012) and other materials (Shi et al. 2017), hybrid protein-solid-state nanopores (Hall et al. 2010) and nanopores with integrated electronic sensors (Rosenstein et al. 2012). In these cases, various derivatization and coupling strategies, many of which are the same as those described above and are well known in the art, can be used. In some embodiments, the first antibody may not be directly connected to the nanopore, but connected nearby (see Example 10 below). Multiple copies of the antibody may be connected to or near the nanopore.
[0196] Finally, the first antibody or the nanopore associated therewith can be specifically labeled with a nanopore detectable label so that even in the absence of the bound biomarker, the identity of the first antibody and the nanopore can be subsequently identified on the nanopore array in a complex multiplexed format. Among many method benefits, this embodiment provides a direct measurement of the absence of specific biomarkers in a complex analyte mixture. Binding can be assessed by gel shift assays. This method is described in more detail in Example 11 below, in which the method is described as a multiplex detection for target molecules.
[0197] Example 2: Attaching the tag to a secondary antibody (detection antibody). The secondary antibody will be attached to a nanopore detectable tag. Poly(ethylene) glycol (PEG)-based tags with a transmembrane voltage gradient from positive (cis side) to negative (trans side) have been reported (US2015 / 0111759 A1 and Kumar (2012)). More recently, tags with negatively charged polynucleotide backbones that require reverse voltage polarity (negative on the cis side and positive on the trans side) have been reported (US2013 / 0264207A1, Fuller (2016) and Stranges (2015)). The oligonucleotide will be modified with a terminal amine for attachment to an NHS ester-containing linker (see for two different methods for attaching such a linker to the detection antibody). Figure 4A and 4B ) connection, but various other modifications of the tag for linker attachment are also well known. The attachment position on the second antibody will be the same as the attachment position used to attach the linker to the first antibody described in the previous paragraph. Although a specific method is used, the goal will be to attach a single tag (or several copies of a tag to increase the probability of signal detection) to each detection antibody. (For the structure and conjugation site of the detection antibody, see Figure 3 Top right.)
[0198] Again, as mentioned above in Example 1, the first antibody or the nanopore associated therewith can be specifically labeled with a nanopore detectable label so that even in the absence of the bound biomarker, the identity of the first antibody or the nanopore can be subsequently identified on the nanopore array in a complex multiplexed format. Among many method benefits, this embodiment provides a direct measurement of the absence of specific biomarkers in a complex analyte mixture. The binding of the tag to the second antibody can be assessed by gel shift assay and / or using a fluorescent label contained in the tag, preferably at the end opposite to the amino modification.
[0199] Example 3: Alternatives to Antibodies Although antibodies are the most commonly used and perhaps the best understood molecules for binding to various targets (antigens), recently, new classes of molecules have emerged, including Affibodies (Lofblom et al. 2010), TM Various antibody mimetics have been produced, including avipep (avipep Pty Ltd), affimers (Tiede et al. 2017), nanotweezers (Suderman et al. 2017), and various other organic small molecules, many of which have been developed as pharmaceutical agents. In addition, fusion proteins composed of antibody fragments can be used instead of complete antibodies.
[0200] Example 4: Types of target antigens (analytes). Although the most typical antigen will be a protein molecule, and many proteins have indeed been identified as biomarkers, antigens can include a variety of other small or macromolecules, including lipids, carbohydrates, DNA, or complex molecules such as glycoproteins or lipoproteins, or larger complexes such as viral particles, thereby again focusing primarily on biomarkers for cancer and other diseases, including but not limited to infectious processes. In addition to pathology, other physiological and pre-disease states can also be identified and monitored using appropriate biomarkers, including pregnancy, aging, drug response, etc. Samples of particular interest will be blood, urine, and other fluids used for non-invasive diagnostics, but will also include tissue biopsies or appropriately preserved archival autopsy material.
[0201] Example 5: Protein-protein and other molecular interactions. In addition to antigen-antibody (or antibody mimics) interactions, the method can also be used to identify other molecular interactions. Key molecular interactions in biology include interactions between proteins, protein-DNA interactions and protein-RNA interactions, the binding of small molecules and coenzyme factors to macromolecules such as drug-enzyme interactions and drug-receptor interactions, and many other interactions (Vidal et al. 2011). Classical biochemical and genetic methods for identifying these interactions have many shortcomings. For example, for protein-protein interactions, gel shift assays can examine the protein interactions of a given bait protein. The method is limited to one bait protein at a time. Similarly, yeast two-hybrid and related methods can identify targets of specific proteins used as bait. Although protein chips using multiple bait proteins can be designed in principle, it is difficult to maintain these surface-bound proteins in a form that can recognize their natural partner proteins, and unlike antibody-based protein chips where many Abs already exist, these protein chips must be developed specifically for each bait protein. Here, the bait protein (or other interacting molecule) will be attached to the nanopore via a flexible linker in such a way that the bait protein retains its structure and binding properties.
[0202] Thus, disclosed herein is a method for identifying protein-protein interactions, wherein a capture antibody (antibody 1) is specific for a bait protein, and a labeled detection antibody (antibody 2) is specific for a potential target protein of the bait. Figure 5As shown, the following series of steps are performed: (1) antibody 1 is conjugated to or near a nanopore that has been or is subsequently inserted into a membrane; (2) a sample containing putative interacting proteins is added to the chip to bind the bait protein and any associated proteins (a cross-linking step can be performed before or after addition to the chip to maintain these protein-protein interactions); (3) a tagged antibody 2 specific for the putative target protein (connected via a cleavable linker if antibody 1 is not directly attached to the pore (e.g., to a surface or membrane); connected via a non-cleavable linker if antibody 1 is directly attached to the nanopore) is added to the chip in an electrolyte solution; (4) cleavage of the tag is performed, if necessary; and (5) a voltage is applied across the membrane and the ionic current is recorded; identification of the expected signal for the tag (blockade of the ionic current) indicates binding of the target to the bait.
[0203] As mentioned above, the concept can be further extended to a form in which the reaction steps (1-3) associated with binding the bait and target to the nanopore complex and the appropriate antibody are performed in the solution phase, and the enriched nanopore-antibody-bait-target tag antibody complex is then applied to the nanopore array and evaluated at the single molecule level. Prior to application to the array, the formation of the complex can be assessed by gel shift assay or using fluorescent labels.
[0204] Although Figure 5 A single capture antibody molecule is shown in , but multiple capture antibodies or small antibody mimics can be bound to the nanopore to increase the chance of capture and therefore increase sensitivity.
[0205] Example 6: Properties of tags. Tags are usually polymer molecules that penetrate the channel of the nanopore to reduce the ionic current to a defined extent when a given voltage is applied across the membrane inserted into the nanopore. Various polymers have been developed for this purpose (US2018 / 0073071 A1, US2015 / 0368710 A1, US2017 / 0058335 A1, and WO 2016 / 154215 A1). Examples include polymers containing PEG, alkanes, peptides / polypeptides, and polynucleotide backbones or combinations thereof. These polymers can then be modified in various ways to expand or reduce their diameter at key locations in the channel, have a greater negative or greater positive total charge or local charge, have more or less polarity, or have affinity properties for the nanopore. Many examples of such tags have been proposed (US2018 / 0073071 A1, US2015 / 0368710 A1, and WO 2016 / 154215 A1). Figure 6 Shown is the separation of ion current readings that can be obtained using different tags entering the pore. Figure 7and 8 Examples of tags are shown, many of which have been synthesized and reported elsewhere (Kumar (2012), Fuller (2016), and Stranges (2016)).
[0206] Example 7: Basic scheme for nanopore-based protein sensing using Antibody 1 and Antibody 2, each directed against a different part of the protein. Figure 1 In the exemplary method presented in : (1) a nanopore labeled with antibody 1 (capture antibody) is inserted into a membrane on a chip, ideally one nanopore per sensor on the array; (2) next, the chip is incubated with the antigen present in the sample; (3) then, typically, the chip is incubated with labeled antibody 2 (detection antibody) in an electrolyte solution; (4) finally, a voltage is applied across the membrane and the resulting ionic current is measured: a sustained blockage of the current indicating entry of the label into the nanopore channel will indicate binding of the antigen to the complex. Washes are performed between incubations as necessary to remove unbound molecules from previous incubations that might inhibit or compete with subsequent steps. The electrolyte solution can be adjusted over a wide range with respect to specific ions and their concentrations, depending on the desired conditions for distinguishing ionic current levels. While test experiments can be performed using a single nanopore setup (e.g., Axopatch, EBS), nanopore arrays have been developed (Fuller et al. 2016) and are desirable for further optimization of the system and are necessary for multiplexing and digital quantification.
[0207] The same antibody can be used as both capture and detection antibody as long as it can bind to different locations on the antigen (eg, a polyclonal antibody that recognizes multiple epitopes on the antigen).
[0208] This basic method can be performed in a form in which the reaction steps related to binding of the biomarker to the nanopore-conjugated antibody 1 and the tagged antibody 2 are performed in the solution phase, for example in a suitable microfluidic device, and the enriched nanopore-antibody-biomarker tag antibody complex is then applied to a nanopore array and evaluated at the single molecule level.
[0209] In some applications, it may be advantageous to perform the microfluidic reaction of the nanopore antibody-antigen binding and wash steps on magnetic beads (e.g., as described in Ng et al. (2018)), but then cleave the nanopore complexes from the beads and detect them on the chip. As described in the previous example, the enriched nanopore-antibody-biomarker tag antibody complexes are applied to a nanopore array and evaluated at the single molecule level. In this case, the nanopore complexes will be linked to the nanopore array via a cleavable linker such as Fig.17 Those presented are tethered to paramagnetic particles.
[0210] exist Figure 1 In the method shown, a single capture antibody (antibody 1) is shown as being connected to the nanopore. If desired, multiple capture antibodies or small antibody mimics (e.g., affibodies, affimers, affimers, etc.) can be connected to the nanopore to increase the probability of target capture, which would be advantageous if the target is present in low abundance and higher sensitivity is required.
[0211] In an exemplary embodiment of Example 7, the capture antibody and the detection antibody can be directed against breast cancer biomarkers including MUC-1, carcinoembryonic antigen, CA-125, and estrogen receptors such as HER2 (Gam 2012; Mueller et al. 2018).
[0212] Alternative methods that can be used to further enhance the sensitivity of the method ( Fig. 9 ) will be the use of nanoscale magnetic beads inlaid with capture antibodies connected to nanopores by biotin-streptavidin, digoxigenin-anti-digoxigenin or any alternative conjugation method described above. In this case, the beads will be used to capture antigen biomarker targets from serum or other samples. The beads will also have chemical substituents on the surface for binding to or near the nanopores (various chemical interaction partners (including but not limited to those mentioned above) can be used for conjugation). The nanopore-bound complex is inserted into the lipid membrane on the nanopore array chip, with one nanopore per sensor (electrode) position. Next, the chip is incubated with a labeled detection antibody specific for the biomarker of interest. This will lead to the identification of bound biomarkers after applying a voltage across the membrane and the nanopores in the capture nanopore channel can distinguish the tags and produce tag-specific ion current blocking. The advantage of using magnetic beads will be enhanced sensitivity, because due to the presence of many capture antibodies on the beads, the chances of binding biomarkers are increased, and the chances of binding detection antibodies are also increased, thereby increasing the possibility of tag capture through the nanopore.
[0213] Capture antibody to bead connection and bead to nanopore connection. In a preferred embodiment, amino-derivatized magnetic beads are incubated with both maleimide NHS ester and biotin NHS ester in a suitable ratio so that the beads will be derivatized with both maleimide and biotin at a ratio of 10: 1 or higher. The subsequent conjugation reaction with the antibody will produce capture antibody-bound beads through a thiol-ene reaction, wherein a small amount of biotin coexists on the beads. Biotin will be used as a binding compound (binding compound 1) to connect the capture antibody-decorated beads to the nanopore with streptavidin (binding compound 2) through a biotin-streptavidin interaction. The resulting nanopore with beads inlaid with capture antibodies is then inserted into a lipid membrane, and the procedure described in the previous paragraph is followed to detect the compound of interest with high sensitivity.
[0214] Example 8: Detection of Antibodies in Serum or Tissues. In infectious disease research, rapid detection of circulating antibodies to viruses, bacteria, or other pathogens for early diagnosis is often highly desirable, as growth and identification of infectious agents can often take several days and may not be possible in some cases. An example of the use of a novel ELISA approach for such purposes has recently been described (Ng et al. (2018)). Similarly, the single-molecule nanopore system described herein can be readily adapted for such purposes and will be particularly useful in assaying several potential infectious agents in a patient. In the simplest scenario, the antigen of interest (e.g., a coat protein on a virus, an immunogenic component of a bacterial cell) can be detected by any of the methods outlined above ( Fig. 10A ) is attached to or near the nanopore, the method comprising using biotin-streptavidin ( Fig. 10B ) interaction or digoxin-anti-digoxin antibody ( Fig. 10C ) interaction. Therefore, the antigen itself will serve as the capture reagent ( Fig. 10A , 10B and 10C). Combined with a flexible linker, this connection method will further increase binding affinity, reduce molecular crowding and increase accessibility to subsequent binding steps. Next, serum with putative antibodies will be added to the chip. Almost all serum proteins containing any serum Ig will be tagged, in which case the bound antibodies will have tags that can be immediately detected in the nanopore. In order to select the serum Ig of interest to reduce complexity, in an alternative strategy, a secondary antibody with a nanopore tag for the captured antibody can be used, the secondary antibody with a nanopore tag being directed to the Fc portion and raised in different species (e.g., goat-anti-human antibody (secondary antibody)) ( Fig.11A ) or, in the case of well-characterized antibodies of interest, anti-idiotypic antibodies, which further improve specificity and allow multiplexing of different serum antibodies on the same nanopore array chip. Collection of labeled secondary anti-Fc or anti-idiotypic antibodies avoids the serum tagging step and reduces costs. As an alternative to the secondary antibody, protein A or G can be used to bind to the primary antibody. Interaction molecules between serum antibodies and secondary antibodies, such as biotin-streptavidin ( Fig. 11B ) or digoxin-anti-digoxin antibodies ( Fig. 11C ). Combined with a flexible linker, this ligation method will further increase binding affinity, reduce molecular crowding, and increase accessibility for subsequent binding steps.
[0215] As mentioned above, to increase the sensitivity of capture for viral or other antibodies, amine-NHS or various other reactivity can be used to connect viral particles (Ricks et al. 2019) or fragments to the nanopore. Since there are many copies of viral coat proteins on viral particles or even viral particle fragments, this provides many sites for binding of serum antibodies. In one approach, viral antibodies can be pre-tagged (non-specifically) ( Fig.12 ), and in the second approach, the serum antibodies may be untagged, while the tag will be present on the secondary antibodies raised against the Fc portion of these primary antibodies ( Fig.13 ).
[0216] As described in Example 12, this method can be adapted to quantify one or more types of viral antibodies by pre-labeling the viral particles or viral proteins bound to the nanopores with a cleavable tag specific for the antigen. After a signal is detected due to the capture of this tag to identify which viral antigen is present on a given nanopore of a particular sensor covering the nanopore array, such as Fig.18 The nanopore array chip is then incubated with serum to capture non-specifically tagged viral antibodies ( Fig.12 ) or untagged viral antibody followed by a nonspecifically tagged secondary antibody ( Fig.13 ), and detect non-specific label signals. Thus, the initial label defines the viral antibodies that can be detected at the positions on the array, and the second label indicates whether the antibodies are actually present.
[0217] As an example of a specific embodiment of the method, nanopores coated with killed Rubella (German measles) or Rubeola (measles) virus particles or nanopores derivatized with Rubella or measles antigens will be used in a microfluidic station to capture the relevant tagged antibodies in a blood sample. The sample is diluted in PBS supplemented with 4% BSA and 0.1% Tetronic 90R4, exposed to the nanopores coated with virus particles or antigens and washed four times with PBS / Tetronic 90R4 in the microfluidic device. Fig. 9 As shown, after washing, the antibodies can be detected. For multiplexing, the derivatized nanopores will also carry a cleavable nanopore tag specific for rubella or measles virus. After cleavage and detection of the tag to determine which antigen is present at each position of the nanopore array (the tag can be directly attached to the nanopore or to the antigen on the nanopore), the chip is incubated with serum antibodies labeled with nonspecific tags (such as Fig.12 ) in PBS / BSA / Tetronic 90R4 or unlabeled serum antibodies, followed by secondary antibodies conjugated to nonspecific tags (e.g. Fig.13 The samples were incubated in PBS / BSA / Tetronic 90R4 to reveal the presence / absence and titer of viral antibodies in serum samples. The viral particles were attached to the nanopores using standard methods described above or by site-specific mutagenesis of amino acids (Chatterjiee et al. 2004).
[0218] This method can also incorporate magnetic beads embedded with viral proteins ( Fig.14 )(Ng et al. (2018)). In this case, beads with clusters of viral proteins are mixed with blood or other samples as a means of capturing multiple copies of antibodies to a given viral protein. The magnetic beads will also have chemical substituents on their surface for binding to or near the nanopores. The resulting complex is inserted into a membrane on a nanopore array, one nanopore per sensor position. Finally, the array is incubated with secondary antibodies targeting the primary antibodies and labeled with a nanopore-detectable tag specific for the target of interest. Application of a voltage across the membrane will allow the tags to be captured and the presence of the viral (or other) antibodies of interest to be determined based on the resulting current blockade signal. The advantage of this approach is that, given the large number of antigenic (viral) proteins on the magnetic beads, even antibodies at very low concentrations in serum will likely be detected. Because this sandwich approach is used, multiple tagged secondary antibodies will be bound, thereby also increasing the likelihood that the tags will enter the nanopore channel to produce the desired signature. Obviously, by using different beads with proteins from different viruses, the same chip can be used to detect different viral targets with high sensitivity on the same chip. Further, quantitative or semi-quantitative multiplexing can be accomplished by mixing virus-specific tags on beads or antigens with non-specific tags on secondary antibodies. The preparation of capture antibody-linked beads and their attachment to nanopores are described in Example 7.
[0219] Another variation of the above method for detecting antigen-antibody complexes commonly found in serum during autoimmune and other disease processes that is closer to the more general method described herein involves the use of both a capture antibody and a detection antibody attached to or in the vicinity of the nanopore ( Fig.15 ). This capture antibody will pull out potential antigen-antibody complexes from the serum. Subsequently, a labeled anti-Fc or anti-idiotypic antibody raised against the antibody in the antigen-antibody complex will flow through the chip, and the label-dependent ion current blocking event will reveal the presence of the antigen-antibody complex in the serum. This variation can optionally include the use of antibody-coated capture beads to further increase sensitivity. Moreover, instead of using an antibody connected to or near the nanopore as a capture reagent to pull out the antigen-antibody complex from the serum, the antigen can be used as a capture agent. In this case, after binding the antibody-antigen complex, a labeled second antibody against the serum antigen will be used for detection.
[0220] If the antigen or capture antibody is attached near the nanopore instead of being attached to the nanopore, the tag will be attached to the detection antibody through a cleavable linker to allow the released tag to reach the nanopore channel. If necessary, the capture antibody and the detection antibody can be replaced with antibody mimics. Antibody mimics are generally substantially smaller than antibody molecules. This can be used to increase the possibility of capture and therefore sensitivity by connecting multiple copies of the antibody mimics to the nanopore or near the nanopore, usually through a flexible linker.
[0221] Finally, as described above, immunodetection reactions can be performed directly on the nanowell array or in solution in a microfluidic chip and then inserted into the membrane of the array for detection.
[0222] Example 9: Multiplexing and quantification of target molecules. By definition, nanopore ion current measurements are at the single molecule level, assuming that a single nanopore is inserted into the membrane above each sensor. In the case of connecting different antibodies (for different target biomarkers) to different nanopores, assuming that the capture antibody or detection antibody has no cross-reactivity with antigens other than the desired antigen, the system can be set up for multiplexing, quantification, or both. For example, using separate flow cells covering different parts of the chip, nanopores with different capture antibodies (for specific target biomarkers) can be placed in each flow cell, resulting in separate areas of the chip each having its own capture antibody. The same sample is then added to each flow cell so that the specific antigen in the sample will be connected to the specific capture antibody. In the third step, labeled detection antibodies can be added to all flow cells or only to flow cells containing capture antibodies for the same antigen protein or other antigens. In the case of separate flow cells, each detection antibody can be labeled with the same label.
[0223] exist Fig.16In the alternative scheme for maximizing the ability to quantify the antigen ratio, an equimolar mixture of nanopores (each for different target biomarkers) bound by capture antibodies can flow through the entire chip. Then, a sample containing an equimolar mixture of antigens and labeled detection antibodies (for the same set of target biomarkers) each with a unique label will flow through the chip. Since this nanopore-based method is unimolecular (digital), it can be quantified by simply counting the number of sensors reporting suitable labels. Assuming that the capture antibody-nanopore is inserted into the membrane with the same efficiency and that the antibodies have the same affinity for their respective antigen targets, this method will be highly quantitative. Therefore, if 1000 sensors show a current indicating label 1, 100 sensors show a current indicating label 2, and 10 sensors show a current indicating label 3, it can be assumed with a reasonable confidence level that the ratio of antigen biomarker targets 1, 2 and 3 contained in the sample is 100:10:1. If some of these assumptions are incorrect, the system can be calibrated accordingly. For example, if some antibodies have a higher affinity, their portion in the antibody mixture will be proportionally reduced.
[0224] An important consideration for all multiplexing approaches is that even using only four distinguishable tags in two different steps, up to 16 different features can be revealed (e.g., the representation of four analytes in four different tissues or four different functional or developmental states of the same tissue).
[0225] Example 10: Alternative scheme where the antibody is attached near the nanopore and the cleavable linker is between the tag and the second antibody: A variation of the above method includes attaching the antibody near the nanopore instead of directly to the nanopore. For example, if the microfabricated hole separates the sensor and the associated membrane, the capture antibody can be directly attached to the surface of the hole using traditional surface conjugation techniques. For example, the surface can be modified with various reactive groups (amino, NHS ester or carboxylic acid, alkyne, tetrazine, biotin, etc.), and the antibody can be modified with partner reactive groups (carboxyl, amino, azide, TCO, streptavidin, etc.). The coupling will be completed under conditions well known in the art. Alternatively, the capture antibody can be directly attached to the membrane using reactions between phospholipids, artificial lipopolymers or modified lipids and the associated reactive chemical part on the antibody. In either case, after incubation with the antigen and the detection antibody tagged as described above, the position of the tag in the resulting surface or membrane-capture antibody-antigen-detection antibody-tag complex is extremely unlikely to be close enough to reach and extend into the nanopore channel. To overcome this obstacle, the tag can be linked to the second antibody via a cleavable linker. After cleavage, the tag is provided with sufficient time to be drawn into and through the nanopore channel with the aid of the electric field. This may require different concentrations of electrolytes and higher voltages than in the basic scheme.
[0226] Thus, the steps of this alternative approach are as follows: (1) incubating a derivatized chip or membrane surface already containing an embedded nanopore with an appropriately derivatized capture antibody; (2) incubating the chip with an antigen-containing sample; (3) incubating with a cleavably tagged detection antibody in an electrolyte solution; (4) cleaving the cleavable linker with a suitable chemical or other cleaving agent to release the tag; and (5) applying a voltage across the membrane and measuring the resulting ionic current: a transient blockage of the ionic current indicating entry of the tag into the nanopore channel would indicate binding of the target antigen to the complex.
[0227] As with the basic scheme, washing steps will be performed between steps as needed to remove previously unbound or unconjugated molecules. In order to greatly increase the likelihood that the tag will be captured by the nanopore, many copies of the same capture antibody can be used to decorate the surface or membrane near the nanopore, or the capture antibody can be aggregated on beads attached to the surface. It is also important to have fast sensing in these situations because the tag will pass through the nanopore channel at a high speed (on the order of nanoseconds to hundreds of nanoseconds, depending on, for example, the nature of the tag, the ionic composition of the buffer, and the applied voltage).
[0228] Various cleavable groups that can be placed in the linker have been described, and for each cleavable group in the cleavable group, there are specific and protein compatible cleavage agents. Examples involving biomarker sensing using nanopores have been described (US 2016 / 0041179 A1), in which cleavable linkers have been designed and placed in various molecules for a variety of purposes, including sequencing by synthesis using fluorescent tags and anchors (US2016 / 0090621 A1), biotin is connected to primers for enrichment of ternary complexes (US62 / 643,633), etc. It is important to avoid sulfhydryls or other groups that are subjected to the cleavage of reducing agents, because these groups can affect immunoglobulin (antibody) subunits, thereby potentially changing their binding properties, so that the group is no longer bound to the antigen with sufficient affinity. Other proteins containing cystine (connected cysteine) can be similarly affected by reducing agents. Fig.17 Included are examples of cleavable linkers that can be used to attach tags to antibodies or other molecules for use in the protocols described herein.
[0229] Example 11: Additional Methods for Detecting Multiple Target Molecules: In this variation ( Fig.18 ), a specific tag is attached to a capture antibody for a given target molecule. Different specific tags are attached to capture antibodies for different target molecules. The capture antibody conjugate with nanopore tags flows through the array, where nanopores with different tagged capture antibodies will be randomly inserted into the membrane in different sites on the chip at approximately the ratio they are in solution. The tag is attached to the capture antibody via a cleavable linker (an example of a cleavable group is described in Fig.17). A voltage is applied across the membrane. After obtaining a record at each position to establish which capture antibodies are associated with each position in the array, the label is cleaved as previously described (US2016 / 0041179 A1). Separated antigen biomarkers pre-labeled with a universal nanopore detectable label (different from any of the specific nanopore detectable labels attached to the capture antibody) present in the sample flow through the chip and bind to the appropriate capture antibody. A voltage is applied across the membrane again and a new current reading is obtained. The presence of a blocking current due to the universal antigen label indicates antigen binding. Since it is already known from the first record which capture antibody is present at the position on the chip, the specific antigen that has been bound can be determined. Therefore, at each position on the array where the specific capture antibody present due to the first record is known, the second record indicates the binding of the antigen, and all such cases (where both specific labels and general label currents are present) are counted to indicate the relative number of different antigens in the sample. An alternative approach (not shown) would be to use a non-cleavable label on the capture antibody. In this case, the subsequent binding of the antigen to its general tag will result in competition between the general tag and the specific tag for entry into the channel of the nanopore under repeated application of voltage (pulses) across the membrane. In contrast to the initial recording with only specific tag current blocking, the current trace of a given hole will appear as a mixture of blocking due to the specific tag and the general tag. Therefore, this change will appear as a switch from specific tag blocking to a mixture of specific tag blocking and general tag blocking, rather than switching from specific tag blocking to general tag blocking.
[0230] Preparation of nanopores with capture antibodies and cleavable tags Fig.19 and 20 First, a cleavable trifunctional linker NHS ester-azo TCO / PEG3-maleimide ( Fig.19 ). The TCO was first coupled to an Fmoc-protected lysine, which could be further coupled to an azo linker via carboxylic acid activation and amide bond formation. Removal of the Fmoc group allowed one more coupling step using maleimide NHS ester. Subsequent activation of the azo linker acid provided NHS ester-azo TCO / PEG3-maleimide. Next, the nanopore-capture antibody-cleavable tag conjugate was prepared ( Fig. 20). The above cleavable trifunctional linker NHS ester-azo TCO / PEG3-maleimide is reacted with an amino tag to produce a tag-azo TCO / PEG3-maleimide conjugate, which can be readily reacted with a tetrazine-modified capture antibody by TCO-tetrazine addition. The resulting tag-azo capture antibody-maleimide conjugate is further reacted with α-hemolysin-SH by thiol-ene addition to provide a nanopore cleavable tag-capture antibody conjugate, wherein the tag can be removed by azo reduction and cleavage upon sodium dithionite treatment.
[0231] This format is flexible and therefore will not be limited to detecting a specific class of target molecules (proteins, nucleic acids, small molecules, etc.) on a given chip. For example, simultaneous detection of protein and DNA biomarkers would be feasible by using appropriate combinations of antibodies, aptamers (Lakhin et al. 2013), or other molecules to specifically bind to these biomarkers.
[0232] In an exemplary embodiment of Example 11, the capture antibodies and detection antibodies can be directed against a large number of cancer markers including PSA, MUC-1, carcinoembryonic antigen, CA-125 and estrogen receptor (Gam 2012; Mueller et al. 2018).
[0233] Example 12: Method for detecting multiple viral antibodies: Just as target molecules can be multiplexed using cleavable tags and multiple capture antibodies with cleavable tags (Example 11), multiple types of viral antibodies can be detected in serum using cleavable tags and viral antigens as capture reagents. In this case, this method can be adapted to quantify one or more types of viral antibodies by pre-labeling viral particles or viral proteins that bind to nanopores (by methods similar to those described for connecting antibodies or beads to nanopores) with cleavable tags specific for the antigen. The nanopores with attached tagged antigens are then inserted into the membrane, one for each sensor on the array chip. Upon application of a voltage across the membrane, the tags will be captured by their respective nanopores to generate a specific ion current blockade signal. This will reveal which antigen is attached to the nanopore in each location. After the first detection step, the tags are cleaved. The nanopore array chip is then incubated with serum or serum protein extracts to capture viral antibodies, which are as Fig.12 Non-specifically labeled viral antibodies in Fig.13In one embodiment, the first tag is attached to an untagged viral antibody followed by a non-specifically tagged secondary antibody. A voltage is again applied across the membrane and the non-specific tag signal is detected. Detection of a signal in this step will reveal the presence of viral antibodies for which this nanopore is specific, as determined by the initial tag detection. A version can also be envisioned in which the first tag is not attached to the antigen on the nanopore, but rather to a location near the nanopore, such as the pore surface or membrane, but in this case the initial tag will be cleaved upon flow through the nanopore and detected instantaneously.
[0234] Example 13: Sample multiplexing: In Examples 9 and 11, multiplexing and quantification of antigens was described. However, this scheme can also be developed to compare multiple samples on the same chip. In the simplest version, the basic scheme of Example 7 is performed, with antibody 1 (capture antibody) attached to the nanopore and tagged antibody 2 (detection antibody), but samples from different tissues, treatments or patients are loaded equally into separate flow cells.
[0235] Methods involving generalized labeling of any or all proteins or other antigenic targets in each sample, each with a different label that can be distinguished in the nanopores, have been described previously (US2016 / 0041179A1). In this case, there is no labeled detection antibody. A single capture antibody is attached to all nanopores in the array, and then an equimolar mixture of differentially labeled samples is added to the chip.
[0236] This article discloses a variation of this method, which combines samples and antigens in multiplexed combinations. In this method, a capture antibody specific for a given antigen target is connected to a nanopore or connected near the nanopore. A large number of such antibodies are used for different antigens of interest, one of which will accidentally bind to each nanopore. Next, a group of several samples are mixed together in equal amounts and added to the chip, each of which is labeled with a unique cleavable tag that binds to a large number of proteins or other targets present in the sample. After cleavage, the current attributable to this tag through the nanopore channel at each position on the array determines the sample derived from the connected antigen. Next, a detection antibody specific for a given antigen with a unique distinguishable nanopore tag is added to the array. A large number of such differentially labeled specific antibodies are used and applied to the chip in equimolar amounts, which are adjusted when necessary according to a predetermined antibody affinity. Depending on whether the capture antibody 1 is directly connected to the nanopore or connected to the surface near the nanopore, the label on the sample detection antibody 2 can be non-cleavable or cleavable, respectively. The ionic current associated with this second set of tags will determine the specific antigen bound at each nanowell location on the array.
[0237] In an exemplary embodiment, there are 5 samples (AE) and 5 antigens of interest (MQ). Cleaving tags A, B, C, D and E will be used to label samples A, B, C, D and E, respectively. Since these cleavable tags are cleaved and pass through the nanopore, the detection antibodies for antigens M, N, O, P and Q can also be labeled with cleavable tags A, B, C, D and E, respectively. In the first set of records, the sample from which the antigen of the binding is derived will be determined, and in the second set of records, which actual antigen is combined will be determined. Using a sufficient number of nanopores, the quantification of the ratio of each antigen in each sample can be determined. As with all the above schemes, antibodies can be replaced with antibody mimics, interacting protein partners (ligands or receptors, etc.), and the target can be a protein or other molecule such as any biomarker of interest.
Claims
1. A method for detecting the presence of a compound of interest in a sample, the method comprising: a) binding a capture compound for the compound of interest or multiple copies of the capture compound to or near the nanopore; b) inserting the nanopore into the resistive barrier; c) contacting the capture compound or the plurality of copies of the capture compound with the sample containing the compound of interest under conditions that allow for association of the compound of interest with the capture compound; d) contacting the compound of interest with the tagged compound or multiple copies of the tagged compound under conditions that allow the tagged compound to attach to the compound of interest, wherein the tagged compound includes at least one tag; e) contacting the nanopore with an electrolyte solution and applying a voltage across the resistive barrier; as well as f) measuring a change in an electronic signal across the nanopore caused by entry of at least one tag of the tagged compound into the nanopore, wherein the tag comprises a polymer molecule; wherein the tag further comprises a modification that enlarges or decreases the diameter of the tag within the nanopore; The presence of the compound of interest is thereby detected.
2. The method of claim 1, wherein step c) occurs before step a).
3. The method of claim 1, wherein step d) occurs before step c). The method according to claim 1 , wherein step b) occurs before step a).
5. A method for detecting the presence of a compound of interest in a sample, the method comprising: a) contacting the nanopore with the magnetic beads and binding compound 2 for connecting the magnetic beads to the nanopore or in the vicinity of the nanopore via binding compound 1, under conditions that allow magnetic beads with multiple copies of the capture compound to which the compound of interest is attached to be attached to or in the vicinity of the nanopore; b) inserting the nanopore into the resistive barrier; c) contacting the capture compound on the magnetic beads with a sample containing the compound of interest under conditions that allow the compound of interest to bind to the capture compound; d) contacting the compound of interest with the tagged compound under conditions that allow the tagged compound to attach to the compound of interest, wherein the tagged compound includes at least one tag; e) contacting the nanopore with an electrolyte solution and applying a voltage across the resistive barrier; as well as f) measuring a change in an electronic signal across the nanopore caused by entry of at least one tag of the tagged compound into the nanopore, The presence of the compound of interest is thereby detected. The method according to claim 5 , wherein step c) occurs before step a).
7. The method according to claim 5, wherein: Step d) occurs before step c).
8. The method of claim 5, wherein step b) occurs before step a).
9. A method for determining the presence and / or relative amounts of a plurality of different compounds of interest in a sample, the method comprising: a) contacting a plurality of nanopores with a plurality of different capture compounds, wherein each capture compound binds to a different compound of interest in the sample, The contacting is under conditions such that each capture compound is bound to or in the vicinity of one of the plurality of nanopores; b) inserting the plurality of nanopores into the resistive barrier; c) contacting the plurality of different capture compounds with the sample, the sample comprising the plurality of different compounds of interest, under conditions that permit binding of each compound of interest to the capture compound; d) contacting the plurality of different compounds of interest with a plurality of different labeled compounds, wherein each tagged compound binds to a different compound of interest, wherein each tagged compound comprises at least one tag, wherein each tagged compound comprises a tag that is different from the other tagged compounds, where the identity of each tagged compound is related to the type of tag, The contacting is under conditions that allow each tagged compound to bind to the compound of interest; e) contacting the plurality of nanopores with an electrolyte solution and applying a voltage across the resistive barrier; f) measuring a change in an electronic signal across each nanopore of the plurality of nanopores caused by at least one tag of each of the tagged compounds entering the nanopore; as well as g) comparing the relative number of each type of tag so detected by the nanopore; The presence and / or relative amounts of the plurality of different compounds of interest in the sample are thereby determined.
10. A method for determining the presence and / or relative amounts of a plurality of different compounds of interest in a sample, the method comprising: a) contacting a plurality of nanopores with a plurality of different capture compounds, wherein each capture compound binds to a different type of compound of interest in the sample, wherein each capture compound comprises at least one tag, wherein each capture compound comprises a tag of a different type than every other type of capture compound, where the identity of each capture compound is associated with the type of tag, The contacting is under conditions such that each capture compound is bound to or in the vicinity of one of the plurality of nanopores; b) inserting multiple nanopores into the resistive barrier; c) contacting the plurality of nanopores with an electrolyte solution and applying a voltage across the resistive barrier; d) measuring a change in an electronic signal across each nanopore of the plurality of nanopores caused by at least one tag of each of the capture compounds entering the nanopore, thereby determining the identity of the capture compound attached near or to each nanopore; e) contacting the plurality of different capture compounds with the sample, the sample comprising the plurality of different compounds of interest, wherein each compound of interest has the same type of tag attached thereto, The contacting is under conditions that allow binding of each compound of interest to the capture compound; f) contacting the plurality of nanopores with an electrolyte solution and applying a voltage across the resistive barrier; g) measuring a change in an electronic signal across each nanopore of a plurality of nanopores caused by entry of the tag for each of the compounds of interest into the nanopore; as well as h) comparing the relative numbers of tags detected by the nanopore; The presence and / or relative amounts of the plurality of different compounds of interest in the sample are thereby determined.
11. A method according to claim 9 or claim 10, wherein step b) occurs before step a).
12. The method of claim 10, wherein the tag attached to the capture compound is cleaved after step d).
13. The method of claim 1, wherein the capture compound or the plurality of copies of the capture compound are attached to the nanopore.
14. The method of claim 1, wherein the capture compound or the plurality of copies of the capture compound are attached in the vicinity of the nanopore.
15. The method of claim 14, wherein the capture compound is an antibody.
16. The method of claim 14, wherein the capture compound is an antibody mimetic.
17. The method of claim 16, wherein the antibody mimetic is one of an affibody, an avibody, an affimer, a nanoclamp, a pharmaceutical agent or an organic small molecule.
18. The method of claim 1, wherein the tagged compound is an antibody.
19. The method of claim 1, wherein the tagged compound is an antibody mimetic.
20. The method of claim 19, wherein the antibody mimetic is one of an affibody, an affimer, an affimer, a nanotweezer, a pharmaceutical agent, or an organic small molecule.
21. The method of claim 20, wherein the compound of interest is an antigen.
22. The method of claim 21, wherein the antigen is one of a biomarker, a protein, a lipid, a carbohydrate, a DNA, a viral particle, or other complex molecules.
23. The method of claim 22, wherein the antigen is one of a glycoprotein, a lipoprotein or other complex molecule.
24. A method for determining molecular interactions of biomolecules, the method comprising: a) attaching the biomolecule or multiple copies of the biomolecule to or near the nanopore; b) inserting the nanopore into the resistive barrier; c) contacting the biomolecule with a sample containing the putative interacting compound under conditions that allow the biomolecule and the putative interacting compound to interact, and performing a cross-linking step to bind the biomolecule and the putative interacting compound; d) contacting the putative interacting compound with the tagged compound under conditions that allow the tagged compound to bind to the putative interacting compound, wherein the tagged compound comprises at least one tag; e) contacting the nanopore with an electrolyte solution and applying a voltage across the resistive barrier; as well as f) measuring a change in an electronic signal across the nanopore caused by entry of at least one tag of the tagged compound into the nanopore, wherein the tag comprises a polymer molecule; wherein the tag further comprises a modification that enlarges or decreases the diameter of the tag within the nanopore; Said molecular interactions of the biomolecules are thereby detected.
25. The method of claim 24, wherein step b) occurs before step a).
26. The method of claim 24, wherein the biomolecule is connected to the nanopore via a flexible linker.
27. The method of claim 24, wherein the tag is attached to the tagged compound via a cleavable linker, and the tag is cleaved from the tagged compound after step d).
28. The method of any one of claims 24 to 27, wherein the biomolecule is one of a biomarker, a protein, a lipid, a carbohydrate, a DNA, a viral particle or other complex molecules.
29. The method of claim 28, wherein the biomolecule is one of a glycoprotein, a lipoprotein or other complex molecule.
30. The method of claim 29, wherein the putative interacting molecule is one of a biomarker, a protein, a lipid, a carbohydrate, a DNA, a viral particle, or other complex molecules.
31. The method of claim 30, wherein the putative interacting molecule is one of a glycoprotein, a lipoprotein or other complexing molecule.
32. The method of claim 31, wherein the labeled compound is one of a biomarker, a protein, a lipid, a carbohydrate, a DNA, a viral particle, or other complex molecules.
33. The method of claim 32, wherein the tagged compound is one of a glycoprotein, a lipoprotein or other complex molecule.
34. The method of claim 33, wherein the tag comprises a polymer molecule.
35. The method of claim 34, wherein the polymer molecule is a polymer comprising one or more of PEG, an alkane, a peptide, a polypeptide, a polynucleotide, or any combination thereof.
36. The method of claim 35, wherein the tag further comprises a modification that enlarges or decreases a diameter of the tag within the nanopore.
37. The method of claim 36, wherein the tag further comprises a modification that changes the charge of the tag.
38. The method of claim 37, wherein the tag comprises one or more of: dSP, C3, C n , PEG, pyrrolidine, spermine, spermidine, nitropyrrole, nitroindole, muscimol, benzimidazole, benzene, 7-deazapurine, 5-substituted pyrimidine, fluorescein-dT, fluorescein, rhodamine, ROX, cyanine dyes, or any combination thereof.
39. The method of claim 38, wherein the nanopore is a solid-state nanopore and wherein step b) occurs before step a).
40. The method of claim 39, wherein the resistive barrier comprises graphene, molybdenum disulfide, or silicon nitride.
41. The method of claim 38, wherein the nanopore comprises a biological nanopore.
42. The method according to claim 41, wherein the nanopore is α-hemolysin, MspA or OmpG or FraC or Aeromonas lysin or other transmembrane pore complexes of the β-barrel type or other types of transmembrane pore complexes.
43. The method of claim 42, wherein the resistive barrier is a lipid bilayer.
44. The method of claim 38, wherein the nanopore is a hybrid protein-solid-state nanopore.
45. The method of claim 44, wherein the nanopore comprises an integrated electronic sensor.
